Skip to main content

Loading market data...

DVA

DaVita Inc.

NYSE • United states

$176.88

+$1.53

(+0.87%)

Source: Yahoo Finance · Quote time Oct 21, 2026 14:15 UTC

Management
Credibility
Score

DaVita Inc. (DVA)

Unavailable

Quotes may be delayed

$11.28B

Market Cap

126,148

Volume

9.6

P/E Ratio

Unavailable

Div Yield

DaVita Inc. Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 2000 16TH STREET, DENVER, CO
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

4 Aug 2026

DaVita Inc. filed Form 10-Q

DaVita Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

4 Aug 2026

DaVita Inc. reported Operating or financial results

DaVita Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

8 Jun 2026

DaVita Inc. reported A material agreement

DaVita Inc. filed an 8-K covering a material agreement, a material financing obligation, shareholder voting results, supporting financial statements or exhibits.

5 May 2026

DaVita Inc. filed Form 10-Q

DaVita Inc. submitted Form 10-Q to the SEC for the period ending Mar 31, 2026.

5 May 2026

DaVita Inc. reported Operating or financial results

DaVita Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$668.96M

Total assets (USD)$17.71B

Total liabilities (USD)$16.63B

Shareholders' equity (USD)−$765.10M

Long-term debt (USD)$8.50B

Debt due within a year (USD)$121.53M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$3.55B	$579.00M	$265.40M	$4.02	10-Q · 4 Aug 2026
Q1 2026	$3.42B	$481.89M	$197.53M	$2.87	10-Q · 5 May 2026
Q4 2025	$3.62B	$561.07M	$566.13M	Unavailable	10-K · 11 Feb 2026
Q3 2025	$3.42B	$505.77M	$150.33M	$2.04	10-Q · 29 Oct 2025
Q2 2025	$3.38B	$537.84M	$199.34M	$2.58	10-Q · 5 Aug 2025
Q1 2025	$3.22B	$438.94M	$162.92M	$2.00	10-Q · 12 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $231.00

30.6% upside potential

📈

Strong Buy

Unavailable

👍

Buy

2

⏸️

Hold

2

📉

Sell

1

5 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 21 Oct 2026, 03:49 UTC Targets range 215.00–265.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

22

Sep 2026

Maughan David Paul

Chief Operating Officer, DKC

Tax withholding

$182.34 per share

7,501 shares

15

Aug 2026

Hollar Jason M.

Director

Grant or award

Unavailable per share

278 shares

15

Aug 2026

DESOER BARBARA J

Director

Grant or award

Unavailable per share

278 shares

15

Aug 2026

Schechter Adam H

Director

Grant or award

Unavailable per share

278 shares

15

Aug 2026

Moore Gregory J.

Director

Grant or award

Unavailable per share

278 shares

15

Aug 2026

Pullin Dennis W

Director

Grant or award

Unavailable per share

278 shares

15

Aug 2026

Schoppert Wendy Lee

Director

Grant or award

Unavailable per share

278 shares

15

Aug 2026

Arway Pamela M

Director

Grant or award

Unavailable per share

278 shares

Top Shareholders

Berkshire Hathaway Inc

28,880,209 shares

-4.054% change

6/30/2026

Vanguard Group Inc

4,154,354 shares

-1.74% change

12/31/2025

Blackrock, Inc.

2,460,987 shares

-11.051% change

6/30/2026

Vanguard Capital Management Llc

2,101,425 shares

-3.614% change

6/30/2026

Morgan Stanley

1,601,710 shares

-3.861% change

6/30/2026

Vanguard Portfolio Management Llc

1,377,914 shares

-6.873% change

6/30/2026

State Street Corp

1,323,019 shares

-2.125% change

6/30/2026

Invesco Ltd.

1,211,917 shares

-17.438% change

6/30/2026

Dimensional Fund Advisors Lp

1,137,814 shares

-0.665% change

6/30/2026

Neuberger Berman Group Llc

925,579 shares

73.953% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 21 Oct 2026, 03:49 UTC· 1 day ago

Research coverage and investment tools

DaVita Inc. (DVA) is a stock listed on the New York Stock Exchange in the United States, in the Health Care sector (Misc Health and Biotechnology Services). Its last price was US$176.88 on 21 Oct 2026. That is 52% of the way from its 52-week low of US$101.00 to its 52-week high of US$247.49. Its market capitalisation was US$11.28 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$3.55B	$579.00M	$265.40M	$4.02	—	16.3%	$320.25M	10-Q · 4 Aug 2026 (opens in a new tab)
Q1 2026	$3.42B	$481.89M	$197.53M	$2.87	—	14.1%	$218.81M	10-Q · 5 May 2026 (opens in a new tab)
Q4 2025	$3.62B	$561.07M	$566.13M	Unavailable	—	15.5%	$395.30M	10-K · 11 Feb 2026 (opens in a new tab)
Q3 2025	$3.42B	$505.77M	$150.33M	$2.04	—	14.8%	$675.44M	10-Q · 29 Oct 2025 (opens in a new tab)
Q2 2025	$3.38B	$537.84M	$199.34M	$2.58	—	15.9%	$203.15M	10-Q · 5 Aug 2025 (opens in a new tab)
Q1 2025	$3.22B	$438.94M	$162.92M	$2.00	—	13.6%	$36.75M	10-Q · 12 May 2025 (opens in a new tab)

Cash and equivalents: $668.96M
Total assets: $17.71B
Total liabilities: $16.63B
Shareholders' equity: −$765.10M
Long-term debt: $8.50B
Debt due within a year: $121.53M

10-Q · 4 Aug 2026

DaVita Inc. filed Form 10-Q (opens in a new tab)

DaVita Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
8-K · 4 Aug 2026

DaVita Inc. reported Operating or financial results (opens in a new tab)

DaVita Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.
8-K · 8 Jun 2026 · Material agreement Signed

DaVita Inc. reported A material agreement (opens in a new tab)

DaVita Inc. filed an 8-K covering a material agreement, a material financing obligation, shareholder voting results, supporting financial statements or exhibits.
10-Q · 5 May 2026

DaVita Inc. filed Form 10-Q (opens in a new tab)

DaVita Inc. submitted Form 10-Q to the SEC for the period ending Mar 31, 2026.
8-K · 5 May 2026

DaVita Inc. reported Operating or financial results (opens in a new tab)

DaVita Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

Insider	Date	Transaction	Shares	Average price	Filing
Maughan David Paul Chief Operating Officer, DKC	22 Sep 2026	Tax withholding (F)	−7,501	$182.34	Form 4 (opens in a new tab)
Hollar Jason M. Director	15 Aug 2026	Grant or award (A)	+278	—	Form 4 (opens in a new tab)
DESOER BARBARA J Director	15 Aug 2026	Grant or award (A)	+278	—	Form 4 (opens in a new tab)
Schechter Adam H Director	15 Aug 2026	Grant or award (A)	+278	—	Form 4 (opens in a new tab)
Moore Gregory J. Director	15 Aug 2026	Grant or award (A)	+278	—	Form 4 (opens in a new tab)
Pullin Dennis W Director	15 Aug 2026	Grant or award (A)	+278	—	Form 4 (opens in a new tab)
Schoppert Wendy Lee Director	15 Aug 2026	Grant or award (A)	+278	—	Form 4 (opens in a new tab)
Arway Pamela M Director	15 Aug 2026	Grant or award (A)	+278	—	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Berkshire Hathaway Inc	6/30/2026	28,880,209	-4.054%
Vanguard Group Inc	12/31/2025	4,154,354	-1.74%
Blackrock, Inc.	6/30/2026	2,460,987	-11.051%
Vanguard Capital Management Llc	6/30/2026	2,101,425	-3.614%
Morgan Stanley	6/30/2026	1,601,710	-3.861%
Vanguard Portfolio Management Llc	6/30/2026	1,377,914	-6.873%
State Street Corp	6/30/2026	1,323,019	-2.125%
Invesco Ltd.	6/30/2026	1,211,917	-17.438%
Dimensional Fund Advisors Lp	6/30/2026	1,137,814	-0.665%
Neuberger Berman Group Llc	6/30/2026	925,579	73.953%

Previous close: 175.35 USD
Day range: 172.39 – 177.33 USD
52-week range: 101.00 – 247.49 USD
Volume: 126,148
Market cap: $11.28B
Average volume: 1,132,715
P/E ratio: 9.6
EPS (FY 2025, diluted): 9.84 USD
Shares outstanding: 63.80M
Beta (5Y monthly): 0.87

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 21 Oct 2026, 14:15 UTC· 17 hours ago

Average volume and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:36 UTC· 1 hour ago

P/E is market cap ÷ trailing 12-month net income from SEC filings.

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for DVA yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.